Skip to content
PoliticalRepoPoliticalRepo

Person

Official portrait of Rep. Lofgren, Zoe [D-CA-18]

Rep. Lofgren, Zoe [D-CA-18]

United States · Official source

Records

8,838 records where Rep. Lofgren, Zoe [D-CA-18] is listed as a sponsor, author, or other actor. Search with topics and years

Bill· HRH.R. 6976 (119th)referred

Duty Status Reform Act

United States · United States Congress · 8 January 2026

Bill· HRH.R. 6835 (119th)open

Veterans STAND Act

United States · United States Congress · 18 December 2025

Bill· HRH.R. 6864 (119th)referred

SAW Act

United States · United States Congress · 18 December 2025

Bill· HRH.R. 6870 (119th)referred

GRACE Act

United States · United States Congress · 18 December 2025

Bill· HRH.R. 6786 (119th)referred

Schedules That Work Act

United States · United States Congress · 17 December 2025

Bill· HRH.R. 6682 (119th)referred

Endometriosis CARE Act

United States · United States Congress · 11 December 2025

Bill· HRH.R. 6579 (119th)referred

Justice for Breonna Taylor Act

United States · United States Congress · 10 December 2025

Justice for Breonna Taylor Act This bill prohibits no-knock warrants, which generally permit law enforcement officers to enter a premises without first identifying their authority and purpose. Specifically, it requires federal law enforcement officers to provide notice of their authority and purpose before executing a warrant. State and local law enforcement agencies that receive funds from the Department of Justice must execute warrants that require the serving officer to provide notice of his or her authority and purpose before forcibly entering a premises.

Bill· HRH.R. 6485 (119th)referred

Skinny Labels, Big Savings Act

United States · United States Congress · 5 December 2025

Skinny Labels, Big Savings Act This bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs. Under current law, the Food and Drug Administration (FDA) may approve generic and biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. , a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics. The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act: submitting or seeking approval of a skinny label for a generic or biosimilar drug; promoting or commercially marketing a drug with skinny labeling approved by the FDA; or describing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug. The bill also applies the safe harbor to similar actions under the Public Health Service Act.

Bill· HRH.R. 6438 (119th)referred

ROBINHOOD Act

United States · United States Congress · 4 December 2025

Bill· HRH.R. 6469 (119th)referred

FREEDOM Act

United States · United States Congress · 4 December 2025

Bill· HRH.R. 6375 (119th)referred

21st Century STEM for Girls and Underrepresented Minorities Act

United States · United States Congress · 3 December 2025

21st Century STEM for Girls and Underrepresented Minorities Act This bill directs the Department of Education to make grants to local educational agencies to pay the costs of carrying out science, technology, engineering, and mathematics (STEM) education activities for girls and underrepresented minorities.

Bill· HRH.R. 6268 (119th)referred

LEAD Act of 2025

United States · United States Congress · 21 November 2025

Bill· HRH.R. 6207 (119th)referred

Chip EQUIP Act

United States · United States Congress · 20 November 2025

Bill· HRH.R. 6209 (119th)referred

American Hemp Protection Act of 2025

United States · United States Congress · 20 November 2025

American Hemp Protection Act of 2025 This bill repeals changes to the regulation of hemp products, which reimpose certain federal controls over some hemp products. Specifically, Congress enacted the FY2026 agriculture appropriations act (P.L. 119-37) on November 12, 2025. Effective November 12, 2026, the act modifies the statutory definition of hemp products that are considered to be lawful. This bill repeals the changes. As background, the 2018 farm bill excluded hemp from the Controlled Substances Act definition of marijuana and defined hemp . As a result, hemp and hemp-derived products at or below the 0.3% delta-9 tetrahydrocannabinol (THC, the psychoactive component of marijuana) concentration threshold were no longer regulated as Schedule I controlled substances. Registration with the Drug Enforcement Administration was no longer required to cultivate or handle hemp and hemp-derived products. However, hemp remained subject to Department of Agriculture and Food and Drug Administration regulation. The 2025 changes to the definition of hemp, include changing the limit to a total THC concentration of not more than 0.3% on a dry weight basis rather than only delta-9 THC, explicitly including industrial hemp, excluding seeds from a cannabis plant that exceed a certain THC concentration, and excluding various types of hemp-derived cannabinoid products. Cannabinoids refer to unique chemical compounds that are found in hemp and marijuana (e.g., THC) and are known to exhibit a range of psychological and physiological effects.

Bill· HRH.R. 6130 (119th)referred

ASAP Act

United States · United States Congress · 19 November 2025

Bill· HRH.R. 6151 (119th)referred

Global Respect Act

United States · United States Congress · 19 November 2025

Bill· HRH.R. 6120 (119th)referred

SROS Act

United States · United States Congress · 18 November 2025